Molecule News and Research

RSS

ATSP-9172 exhibits on-target binding activity in human prostate cancer model

Aileron Therapeutics, Inc. today announced new preclinical data demonstrating that ATSP-9172, its Stapled Peptide inhibitor of HIF-1α-dependent transcription, exhibits on-target binding activity, favorable pharmacokinetic properties and potent in vivo efficacy in a human prostate cancer model.

12 Apr 2013

Ozone attacks lung surface fluids, causes severe respiratory problems

Research at Birkbeck, University of London uses world-leading neutron sources at ILL and ISIS to demonstrate ozone attacks on lung surface fluids.

12 Apr 2013

UT MD Anderson scientist receives AACR-CRI Lloyd J. Old Award in Cancer Immunology

The scientist whose discoveries led to the first drug approved for metastatic melanoma by "treating the immune system, not the cancer," also is the first to receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology.

12 Apr 2013

Study shows hsa-miR-146a overexpressed in most metastatic tumors

In order to kill, bladder cancer must metastasize, most commonly to the lung - what are the differences between bladder cancers that do and do not make this deadly transition? Research presented by the Director of the University of Colorado Cancer Center at the AACR Annual Meeting 2013 shows that one big difference is a little molecule known as hsa-miR-146a.

11 Apr 2013

Study: microRNA is designed to stop proliferation of prostate cancer cells

The most recent in a series of studies from a team at the UC Davis Comprehensive Cancer Center has shown that a single molecule is at the heart of one of the most basic survival tactics of prostate cancer cells.

10 Apr 2013

Tiny proteins prevent bacterial gene transcription

In the search for new antibiotics, researchers are taking an unusual approach: They are developing peptides, short chains of protein building blocks that effectively inhibit a key enzyme of bacterial metabolism.

10 Apr 2013

Researchers develop new strategy to control inflammation without serious side effects

A potential new strategy to developing new drugs to control inflammation without serious side effects has been found by Georgia State University researchers and international colleagues.

10 Apr 2013

Researchers discover novel protein that governs metastasis and chemoresistance in pediatric bone cancer

Human osteosarcoma samples are hard to come by, making the disease difficult to study. However, K9 bone cancer is genetically indistinguishable from the human form of the disease, and over 10,000 canine patients develop the disease every year.

10 Apr 2013

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Onconova Therapeutics, Inc., a development-stage pharmaceutical company focused on discovering and developing novel small molecule drug products to treat cancer, today announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented today at the American Association for Cancer Research Annual Meeting.

10 Apr 2013

Research: ACOT7 enzyme keeps neurons' fat levels under control

We're all fatheads. That is, our brain cells are packed with fat molecules, more of them than almost any other cell type. Still, if the brain cells' fat content gets too high, they'll be in trouble. In a recent study in mice, researchers at Johns Hopkins pinpointed an enzyme that keeps neurons' fat levels under control, and may be implicated in human neurological diseases.

9 Apr 2013

Researchers design drug to block incidence of head, neck cancer caused by HPV virus

Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy.

9 Apr 2013

Quest PharmaTech to develop, market anti-PSA IgE technology for cancer treatment

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has recently signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer.

9 Apr 2013

Researchers explore how blocking EGFR changes signaling in glioblastoma cells

Proteins that control cell growth are often mutated in cancer, and their aberrant signaling drives the wild proliferation of cells that gives rise to tumors. One such protein, the epidermal growth factor receptor, fuels a wide variety of cancers-including a highly malignant brain cancer known as glioblastoma.

9 Apr 2013

Certain brain tumors develop drug resistance by exploiting normal cellular signaling pathways

Proteins that control cell growth are often mutated in cancer, and their aberrant signaling drives the wild proliferation of cells that gives rise to tumors.

9 Apr 2013

FDA approves PROLENSA for treatment of inflammation, pain after cataract surgery

Bausch + Lomb, the global eye health company, today announced that the U.S. Food and Drug Administration has approved the company's New Drug Application for PROLENSA (bromfenac ophthalmic solution) 0.07 percent prescription eye drop, an innovative once-daily nonsteroidal anti-inflammatory drug for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

9 Apr 2013

Study sheds light on role of retinoic acid in tissue development

In a ground-breaking study, researchers from the RIKEN Brain Science Institute in Japan report a new technique that allows them to visualize the distribution of retinoic acid in a live zebrafish embryo, in real-time.

9 Apr 2013

Johns Hopkins researchers find how gout-linked genetic mutation contributes to disease

Johns Hopkins scientists have found out how a gout-linked genetic mutation contributes to the disease: by causing a breakdown in a cellular pump that clears an acidic waste product from the bloodstream.

9 Apr 2013

Researchers discover that fruit fly mutation holds clues for treating motor neuron diseases

A team of researchers, led by Marc Freeman, PhD, an early career scientist with the Howard Hughes Medical Institute and associate professor of neurobiology at the University of Massachusetts Medical School have discovered a gene in the fruit fly Drosophila melanogaster that, when mutant, blocks the self-destruction of damaged axons, which could hold clues to treating motor neuron diseases, such as amyotrophic lateral sclerosis.

9 Apr 2013

Physician-researcher to lead pediatric Dream Team to create new treatments for childhood cancers

A physician-researcher from The Children's Hospital of Philadelphia will lead the first-ever pediatric "Dream Team" solely focused on creating new treatments for the most challenging childhood cancers.

8 Apr 2013

KYTHERA Biopharmaceuticals presents Phase IIIb study results of ATX-101

KYTHERA Biopharmaceuticals, Inc. today announced positive interim results from a Phase IIIb, multicenter, open-label study (ATX-101-11-26) of ATX-101 during the "Innovations and Renewals" session of the 11th Anti-Aging Medicine World Congress, April 4-6, Monte Carlo, Monaco.

8 Apr 2013

Molecule News and Research

ATSP-9172 exhibits on-target binding activity in human prostate cancer model

Ozone attacks lung surface fluids, causes severe respiratory problems

UT MD Anderson scientist receives AACR-CRI Lloyd J. Old Award in Cancer Immunology

Study shows hsa-miR-146a overexpressed in most metastatic tumors

Study: microRNA is designed to stop proliferation of prostate cancer cells

Tiny proteins prevent bacterial gene transcription

Researchers develop new strategy to control inflammation without serious side effects

Researchers discover novel protein that governs metastasis and chemoresistance in pediatric bone cancer

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Research: ACOT7 enzyme keeps neurons' fat levels under control

Researchers design drug to block incidence of head, neck cancer caused by HPV virus

Quest PharmaTech to develop, market anti-PSA IgE technology for cancer treatment

Researchers explore how blocking EGFR changes signaling in glioblastoma cells

Certain brain tumors develop drug resistance by exploiting normal cellular signaling pathways

FDA approves PROLENSA for treatment of inflammation, pain after cataract surgery

Study sheds light on role of retinoic acid in tissue development

Johns Hopkins researchers find how gout-linked genetic mutation contributes to disease

Researchers discover that fruit fly mutation holds clues for treating motor neuron diseases

Physician-researcher to lead pediatric Dream Team to create new treatments for childhood cancers

KYTHERA Biopharmaceuticals presents Phase IIIb study results of ATX-101

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News